Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upsher Launches K-Dur Generic With Exclusivity; FTC Hearing In December

Executive Summary

Upsher-Smith expects to be the only generic competitor to Schering-Plough's K-Dur until March 1, 2002.

You may also be interested in...



FTC K-Dur Case Incorrectly Defines Market, Judge Says In Ruling For Schering

Merck-Medco's decision not to separately list Schering-Plough's K-Dur on its formulary is evidence that the drug is therapeutically substitutable and competes with other versions of potassium chloride, an administrative law judge said

FTC K-Dur Case Incorrectly Defines Market, Judge Says In Ruling For Schering

Merck-Medco's decision not to separately list Schering-Plough's K-Dur on its formulary is evidence that the drug is therapeutically substitutable and competes with other versions of potassium chloride, an administrative law judge said

Andrx Plans Diltiazem ANDA Amendment In May; Biovail Delists Tiazac Patent

Andrx plans to amend its ANDA for a generic version of Biovail's Tiazac in May following a request by FDA for additional data, the company said

Related Content

UsernamePublicRestriction

Register

PS038487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel